The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis. 

The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions. The inflammatory heterogeneity in CRS impact on clinical phenotypes and disease severity is discussed in depth and is exemplified nicely with clinical cases. 

To be added 

The lecture provides an exhaustive description of diagnostic, monitoring, response, predictive and prognostic biomarkers for the T2 immune response, with indications when and how to use in clinical practice followed by an illustrative case report on the value of T2 biomarkers for a non-response to biological intervention in severe asthma. 

The lecture describes the two major types of gastro-intestinal inflammatory diseases, IgE and non-IgE, with a special focus on eosinophilic esophagitis, gastritis and colitis. The role of IL 13, IL-5, eotaxin, integrins, epithelial derived cytokines, innate lymphoid cells, genetic defects and environmental insults is discussed in depth in association with personalized treatment approaches. Case reports guide the learner in differentiating the atopic and non-atopic phenotypes of eosinophilic esophagitis. 

The lecture describes the two types of chronic rhinosinusitis, with and without nasal polyps, linking its pathogenesis(the complex interplay between the immune-inflammatory response, epithelial barrier defect, mucus and coagulation abnormalities and microbiome) to biomarkers guiding treatment decisions. The inflammatory heterogeneity in CRS impact on clinical phenotypes and disease severity is discussed in depth and is exemplified nicely with clinical cases. 

Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

Understand the state of omics science specific to asthma and allergic diseases with the current and potential applicability of omics in clinical disease prediction, treatment, and management.

OVERVIEW

This is a non-promotional, non-CME disease state educational webcast brought to you by EAACI in collaboration with and paid for by GlaxoSmithKline

This webcast is a 4-part series. The topics focus on HES pathophysiology, HES diagnosis and differential diagnosis, HES complications, and HES multidisciplinary assessment.  HES is a heterogeneous group of rare disorders characterised by blood hypereosinophilia, organ dysfunction or damage attributable to tissue hypereosinophilia. The speakers will provide detail on the pathophysiology of HES, with an overview of the causes and variants of HES; discuss how to investigate HES and differentiate it from other diseases; highlight the complications, signs and symptoms that may be associated with HES; and provide clinical insight on the importance of a multidisciplinary approach for personalised assessment and treatment for patients with HES.

EDUCATIONAL OUTCOME/OBJECTIVES

To gain an understanding and clinical insight into:

• the pathogenic role of eosinophils in HES, the mechanisms resulting in eosinophil expansion and the pathogenic contribution of other cells/mediators to HES
• the diagnosis of HES and identifying the cause, how to rule out other disease when diagnosing HES and identify current markers for HES variants
• the broad spectrum of complications associated with HES, and understand the importance of monitoring organs at risk, variability of complications in different disease variants and the nature of the complication in patients with HES
• improving communication between the primary care physician and specialists and understanding why efficient multidisciplinary patient monitoring and treatment is needed.

An in-depth, interactive e-learning resource aimed at improving the diagnosis and management of T2 diseases as long-term conditions for children and adults.

This first educational module focuses on the T2 complex endotype and aims to define and understand the pathogenesis of T2 immune-inflammatory response, its biomarkers and visible properties, adapted to specialized care (specialists in allergy and clinical immunology, pneumology, ENT, dermatology, paediatrics). 

The module unfolds in three stages:

AVAILABLE NOW: Purchase the T2 module/s of your choice via myeaaci.org or education.eaaci.org. This includes outstanding lectures on different aspects of T2 Diseases including clinical case studies, instrumental to better understand the disease and implement their teachings within your clinical practice. Please note that in order to access these platforms you need to have an EAACI account. You can always open your account free of charge.

AVAILABLE  STARTING IN APRIL: Purchase an add-on to your module, and take part in a Live Q&A session with the key opinion leaders. This is your opportunity to ask questions and dive deeper into the topic of your choice. The live Q&A will then be recorded, for you to watch at any convenient time. You will be able to e-mail the speaker with any further questions in written form.

AVAILABLE IN JUNE: Purchase an add-on to your module, take a short multiple-choice assessment, and you will be able to get CME Accreditation from the knowledge you have gained.